Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2018
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2018
SUMMARY
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 33 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The latest report Complement C5 - Pipeline Review, H2 2018, outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.
Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 4, 5, 2, 1, 15 and 1 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Hematological Disorders, Immunology, Ophthalmology, Gastrointestinal, Cardiovascular, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Oncology, Other Diseases, Respiratory and Undisclosed which include indications Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Myasthenia Gravis, Chronic Inflammation, Autoimmune Disorders, Atopic Keratoconjunctivitis, Bullous Pemphigoid, Choroidal Neovascularization, Geographic Atrophy, Intermediate Uveitis, Lupus Nephritis, Neuromyelitis Optica (Devic’s Syndrome), Posterior Uveitis, Acute Lung Injury, Age Related Macular Degeneration, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Bacterial Sepsis, Cardiovascular Inflammation, Community Acquired Pneumonia, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Glomerulonephritis, Guillain-Barre Syndrome, Hidradenitis Suppurativa, Inflammation, Ischemia, Ischemia Reperfusion Injury, Juvenile Macular Degeneration (Stargardt Disease), Liver Transplant Rejection, Lung Adenocarcinoma, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Polypoidal Choroidal Vasculopathy, Rheumatoid Arthritis, Sepsis, Septic Shock, Subarachnoid Hemorrhage, Traumatic Brain Injury, Typical Hemolytic Uremic Syndrome (Shiga-Toxin Associated Hemolytic Uremic Syndrome), Unspecified, Uveitis and Wet (Neovascular/Exudative) Macular Degeneration.
Furthermore, this report also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 33 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The latest report Complement C5 - Pipeline Review, H2 2018, outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.
Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 4, 5, 2, 1, 15 and 1 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Hematological Disorders, Immunology, Ophthalmology, Gastrointestinal, Cardiovascular, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Oncology, Other Diseases, Respiratory and Undisclosed which include indications Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Myasthenia Gravis, Chronic Inflammation, Autoimmune Disorders, Atopic Keratoconjunctivitis, Bullous Pemphigoid, Choroidal Neovascularization, Geographic Atrophy, Intermediate Uveitis, Lupus Nephritis, Neuromyelitis Optica (Devic’s Syndrome), Posterior Uveitis, Acute Lung Injury, Age Related Macular Degeneration, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Bacterial Sepsis, Cardiovascular Inflammation, Community Acquired Pneumonia, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Glomerulonephritis, Guillain-Barre Syndrome, Hidradenitis Suppurativa, Inflammation, Ischemia, Ischemia Reperfusion Injury, Juvenile Macular Degeneration (Stargardt Disease), Liver Transplant Rejection, Lung Adenocarcinoma, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Polypoidal Choroidal Vasculopathy, Rheumatoid Arthritis, Sepsis, Septic Shock, Subarachnoid Hemorrhage, Traumatic Brain Injury, Typical Hemolytic Uremic Syndrome (Shiga-Toxin Associated Hemolytic Uremic Syndrome), Unspecified, Uveitis and Wet (Neovascular/Exudative) Macular Degeneration.
Furthermore, this report also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
- The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Chugai Pharmaceutical Co Ltd
InflaRx NV
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Noxxon Pharma AG
Ophthotech Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Swedish Orphan Biovitrum AB
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles
AcPepA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AOND-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacincaptad pegol sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bikaciomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cemdisiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coversin LA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit C3 and C5 for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Complement C5 for Age Related Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mubodina - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-9405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nomacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXD-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Inhibit Complement C5 for Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RA-101295 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RA-101348 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab next generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-3918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOBI-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Coversin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tesidolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zilucoplan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zilucoplan XR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Products
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones
Featured News & Press Releases
Oct 04, 2018: Ophthotech completes patient recruitment as planned for its phase 2b clinical trial of Zimura monotherapy for geographic atrophy secondary to dry age-related macular degeneration
Sep 30, 2018: Akari Therapeutics announces new clinical data in post-transplant thrombotic microangiopathies
Sep 28, 2018: Ra Pharma reports positive data from Phase lb trial of zilucoplan
Sep 24, 2018: Alexion announces successful phase 3 PREVENT Study Of soliris (Eculizumab) in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Sep 12, 2018: Akari Therapeutics announces new preclinical rheumatoid arthritis data and new clinical data in patients with bullous pemphigoid, highlighting potential advantages of coversin’s bifunctional activity inhibiting both the complement and leukotriene inflamma
Sep 05, 2018: Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program
Aug 28, 2018: InflaRx To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1
Aug 20, 2018: FDA accepts Priority Review of ALXN1210 as a treatment for patients with paroxysmal nocturnal hemoglobinuria in the US
Aug 08, 2018: Ra Pharmaceuticals announces early completion of enrollment in gMG Phase 2 program
Jul 02, 2018: Alexion Pharma Korea’s aHUS therapy Soliris gains coverage
Jun 28, 2018: InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis
Jun 28, 2018: Alexion Submits Application For Approval Of ALXN1210 as a Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The European Union (EU)
Jun 19, 2018: Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the U.S.
Jun 15, 2018: Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association
Jun 14, 2018: Alexion Announces Selection Of Positive Phase 3 Clinical Data For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) For Late-Breaking Oral Presentation At Annual Conference Of The European Hematology Association (EHA)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Chugai Pharmaceutical Co Ltd
InflaRx NV
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Noxxon Pharma AG
Ophthotech Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Swedish Orphan Biovitrum AB
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles
AcPepA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AOND-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacincaptad pegol sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bikaciomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cemdisiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coversin LA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit C3 and C5 for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Complement C5 for Age Related Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mubodina - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-9405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nomacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXD-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Inhibit Complement C5 for Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RA-101295 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RA-101348 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab next generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-3918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOBI-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Coversin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tesidolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zilucoplan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zilucoplan XR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Products
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones
Featured News & Press Releases
Oct 04, 2018: Ophthotech completes patient recruitment as planned for its phase 2b clinical trial of Zimura monotherapy for geographic atrophy secondary to dry age-related macular degeneration
Sep 30, 2018: Akari Therapeutics announces new clinical data in post-transplant thrombotic microangiopathies
Sep 28, 2018: Ra Pharma reports positive data from Phase lb trial of zilucoplan
Sep 24, 2018: Alexion announces successful phase 3 PREVENT Study Of soliris (Eculizumab) in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Sep 12, 2018: Akari Therapeutics announces new preclinical rheumatoid arthritis data and new clinical data in patients with bullous pemphigoid, highlighting potential advantages of coversin’s bifunctional activity inhibiting both the complement and leukotriene inflamma
Sep 05, 2018: Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program
Aug 28, 2018: InflaRx To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1
Aug 20, 2018: FDA accepts Priority Review of ALXN1210 as a treatment for patients with paroxysmal nocturnal hemoglobinuria in the US
Aug 08, 2018: Ra Pharmaceuticals announces early completion of enrollment in gMG Phase 2 program
Jul 02, 2018: Alexion Pharma Korea’s aHUS therapy Soliris gains coverage
Jun 28, 2018: InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis
Jun 28, 2018: Alexion Submits Application For Approval Of ALXN1210 as a Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The European Union (EU)
Jun 19, 2018: Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the U.S.
Jun 15, 2018: Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association
Jun 14, 2018: Alexion Announces Selection Of Positive Phase 3 Clinical Data For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) For Late-Breaking Oral Presentation At Annual Conference Of The European Hematology Association (EHA)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Akari Therapeutics Plc, H2 2018
Pipeline by Alexion Pharmaceuticals Inc, H2 2018
Pipeline by Alnylam Pharmaceuticals Inc, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
Pipeline by InflaRx NV, H2 2018
Pipeline by ISU ABXIS Co Ltd, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by NovelMed Therapeutics Inc, H2 2018
Pipeline by Noxxon Pharma AG, H2 2018
Pipeline by Ophthotech Corp, H2 2018
Pipeline by Ra Pharmaceuticals Inc, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Swedish Orphan Biovitrum AB, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Akari Therapeutics Plc, H2 2018
Pipeline by Alexion Pharmaceuticals Inc, H2 2018
Pipeline by Alnylam Pharmaceuticals Inc, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
Pipeline by InflaRx NV, H2 2018
Pipeline by ISU ABXIS Co Ltd, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by NovelMed Therapeutics Inc, H2 2018
Pipeline by Noxxon Pharma AG, H2 2018
Pipeline by Ophthotech Corp, H2 2018
Pipeline by Ra Pharmaceuticals Inc, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Swedish Orphan Biovitrum AB, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Chugai Pharmaceutical Co Ltd
InflaRx NV
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Noxxon Pharma AG
Ophthotech Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Swedish Orphan Biovitrum AB
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Chugai Pharmaceutical Co Ltd
InflaRx NV
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Noxxon Pharma AG
Ophthotech Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Swedish Orphan Biovitrum AB
